72 results on '"Kugathasan S"'
Search Results
2. P115 Ustekinumab in DEVELOP: A safety analysis from an Inflammatory Bowel Disease multicenter, prospective, long-term registry of paediatric patients
3. P711 Stool microbiome communities predict remission in pediatric Crohn’s disease patients even after start of treatment
4. Complexity of Secretory Chemokines in Human Intestinal Organoid Cultures Ex Vivo
5. P089 Long ncRNA Landscape in the Rectum of Treatment Naïve Early Onset Ulcerative Colitis Highlights Association with Severity and Early and Late Disease Outcome, with Potential Role in Epithelial Metabolic Functions
6. OP32 Stool microbiome communities predict remission in treatment-naïve Pediatric Crohn’s Disease patients
7. DOP89 Pre-treatment mucosal inflammatory and wound healing gene programmes reveal mechanisms associated with future stricturing behaviour during 5-year follow-up in paediatric Crohn’s disease
8. African Ancestry Proportion Influences Ileal Gene Expression in Inflammatory Bowel Disease
9. Diarrhea
10. Single-cell analysis of Crohn’s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy
11. NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease
12. DOP008 Safety of adalimumab in children and adolescents with moderate-to-severe Crohn’s disease: interim results of the CAPE registry
13. The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn's disease - a phase 1 trial with three doses
14. Safety and Efficacy of Autologous and Metabolically Fit Bone Marrow Mesenchymal Stromal Cells (BM-MSC) in Medically Refractory Crohn's Disease (CD)
15. O-11: Real world outcomes of contemporary treatments in children with Crohn’s disease: observations from the pediatric IBD collaborative research group registry
16. 15 Serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with inflammatory bowel disease: DEVELOP registry data
17. P436 Malignancies in children receiving infliximab and other inflammatory bowel disease therapies: an inflammatory bowel disease multicenter, prospective, long-term registry of pediatric patients (DEVELOP) registry data
18. PMO-111 Should all patients with locally advanced pancreatic cancer be offered intraoperative assessment?
19. Crohn's Disease and Genetic Hitchhiking at IBD5
20. Validated method to detect distinct methylation patterns in patients with ulcerative colitis; including IL-10.
21. S03 Association of DYM gene with growth impairment in pediatric Crohn's disease
22. Five-year incidence of surgery in a prospectively followed cohort of pediatric patients with Crohnʼs Disease
23. IL-27 mediates STAT1/STAT3 activation in human intestinal epithelial cells and regulates IL-8, IL-6 and wound healing
24. P014 ANTI-INFLAMMATORY ROLE OF IL-27 IN TNF-ALPHA INDUCED INTESTINAL INFLAMMATION
25. O07 PREDICTORS OF CLINICAL OUTCOME IN CHILDREN WITH ULCERATIVE COLITIS (UC)
26. Brief Report: Development of the Inflammatory Bowel Disease Family Responsibility Questionnaire
27. P192 - Disease duration does not affect outcome following infliximab therapy in children with Crohn's disease
28. African and European genetic admixture in African American IBD patients
29. Growth impairment in pediatric Inflammatory Bowel Disease
30. Growth impairment in pediatric Inflammatory Bowel Disease: Role of parental heights and genetic variants
31. Disease Duration Does Not Affect Outcome Following Infliximab in Children with Crohnʼs Disease
32. Genetic variants in the autophagy pathway contribute to paediatric Crohn's disease
33. P044 RETROSPECTIVE EVALUATION OF THE SAFETY AND EFFECT OF ADALIMUMAB THERAPY (RESEAT) IN PEDIATRIC CROHN'S DISEASE
34. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease
35. The effects of Infliximab therapy on health-related quality of life in pediatric crohnʼs disease
36. Linear growth during infliximab therapy: Results of the REACH multicenter study
37. The effects of Infliximab therapy on health-related quality of life in pediatric crohnʼs disease
38. Linear growth during infliximab therapy
39. Linear Growth During Infliximab Therapy: Results of the REACH Multicenter Study
40. Improvement in a Biomarker of Bone Formation during Infliximab Therapy in Pediatric Crohn's Disease: Results of the REACH Study
41. The Effects of Infliximab Therapy on Health-Related Quality of Life in Pediatric Crohn's Disease
42. CARD15 & IBD5 DO NOT CONTRIBUTE TO CROHN??S DISEASE (CD) SUSCEPTIBILITY IN AFRICAN-AMERICAN & HISPANIC CHILDREN; A MULTI-CENTER STUDY
43. RESOURCE UTILIZATION FOR CHILDREN WITH NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE
44. CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn’s disease
45. AN OPEN-LABEL SAFETY, TOLERABILITY, AND EFFICACY STUDY OF NATALIZUMAB IN ADOLESCENTS WITH MODERATELY TO SEVERELY ACTIVE CROHNʼS DISEASE
46. BODY MASS INDEX (BMI) OF IBD CHILDREN AT DIAGNOSIS; THE EFFECTS OF OBESITY EPIDEMIC
47. P0687 CHARACTERIZATION OF HEIGHT AND WEIGHT PATTERNS IN NEWLY DIAGNOSED CHILDREN WITH INFLAMMATORY BOWEL DISEASE (IBD)
48. P0666 LAB PARAMETERS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE (IBD) AT DIAGNOSIS
49. P0615 STEROID THERAPY IN THE AGE OF INFLIXIMAB (IFX): IMMEDIATE AND 1 YEAR OUTCOME IN NEWLY DIAGNOSED CHILDREN WITH CROHN DISEASE (CD)
50. O0106 THE INCIDENCE AND PREVALENCE OF PEDIATRIC INFLAMMATORY BOWEL DISEASE (IBD) IN THE USA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.